<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T08:24:25Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:10174028" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:10174028</identifier>
        <datestamp>2023-05-12</datestamp>
        <setSpec>bmjo</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">BMJ Open</journal-id>
              <journal-id journal-id-type="iso-abbrev">BMJ Open</journal-id>
              <journal-id journal-id-type="hwp">bmjopen</journal-id>
              <journal-id journal-id-type="publisher-id">bmjopen</journal-id>
              <journal-title-group>
                <journal-title>BMJ Open</journal-title>
              </journal-title-group>
              <issn pub-type="epub">2044-6055</issn>
              <publisher>
                <publisher-name>BMJ Publishing Group</publisher-name>
                <publisher-loc>BMA House, Tavistock Square, London, WC1H 9JR</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC10174028</article-id>
              <article-id pub-id-type="pmcid">PMC10174028</article-id>
              <article-id pub-id-type="pmc-uid">10174028</article-id>
              <article-id pub-id-type="pmid">37156577</article-id>
              <article-id pub-id-type="pmid">37156577</article-id>
              <article-id pub-id-type="publisher-id">bmjopen-2022-071396</article-id>
              <article-id pub-id-type="doi">10.1136/bmjopen-2022-071396</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Diabetes and Endocrinology</subject>
                </subj-group>
                <subj-group subj-group-type="hwp-journal-coll">
                  <subject>1506</subject>
                  <subject>1843</subject>
                </subj-group>
                <series-title>Protocol</series-title>
              </article-categories>
              <title-group>
                <article-title>Text message-based intervention, Keeping in Touch (KiT), to support youth as they transition to adult type 1 diabetes care: a protocol for a multisite randomised controlled superiority trial</article-title>
              </title-group>
              <contrib-group>
                <contrib id="author-103777350" contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-4279-1723</contrib-id>
                  <name>
                    <surname>Sanmugalingham</surname>
                    <given-names>Geetha</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">1</xref>
                </contrib>
                <contrib id="author-104103671" contrib-type="author">
                  <name>
                    <surname>Mok</surname>
                    <given-names>Elise</given-names>
                  </name>
                  <xref rid="aff2" ref-type="aff">2</xref>
                </contrib>
                <contrib id="author-44311560" contrib-type="author">
                  <name>
                    <surname>Cafazzo</surname>
                    <given-names>Joseph A</given-names>
                  </name>
                  <xref rid="aff3" ref-type="aff">3</xref>
                  <xref rid="aff4" ref-type="aff">4</xref>
                  <xref rid="aff5" ref-type="aff">5</xref>
                  <xref rid="aff6" ref-type="aff">6</xref>
                </contrib>
                <contrib id="author-96538285" contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-3429-1865</contrib-id>
                  <name>
                    <surname>Desveaux</surname>
                    <given-names>Laura</given-names>
                  </name>
                  <xref rid="aff3" ref-type="aff">3</xref>
                  <xref rid="aff7" ref-type="aff">7</xref>
                  <xref rid="aff8" ref-type="aff">8</xref>
                </contrib>
                <contrib id="author-90518066" contrib-type="author">
                  <name>
                    <surname>Brazeau</surname>
                    <given-names>Anne-Sophie</given-names>
                  </name>
                  <xref rid="aff9" ref-type="aff">9</xref>
                </contrib>
                <contrib id="author-82789119" contrib-type="author">
                  <name>
                    <surname>Booth</surname>
                    <given-names>Gillian L</given-names>
                  </name>
                  <xref rid="aff3" ref-type="aff">3</xref>
                  <xref rid="aff10" ref-type="aff">10</xref>
                  <xref rid="aff11" ref-type="aff">11</xref>
                  <xref rid="aff12" ref-type="aff">12</xref>
                </contrib>
                <contrib id="author-104104020" contrib-type="author">
                  <name>
                    <surname>Greenberg</surname>
                    <given-names>Marley</given-names>
                  </name>
                  <xref rid="aff13" ref-type="aff">13</xref>
                  <xref rid="aff14" ref-type="aff">14</xref>
                </contrib>
                <contrib id="author-104104055" contrib-type="author">
                  <name>
                    <surname>Kichler</surname>
                    <given-names>Jessica</given-names>
                  </name>
                  <xref rid="aff15" ref-type="aff">15</xref>
                </contrib>
                <contrib id="author-73033134" contrib-type="author">
                  <name>
                    <surname>Rac</surname>
                    <given-names>Valeria E</given-names>
                  </name>
                  <xref rid="aff3" ref-type="aff">3</xref>
                  <xref rid="aff16" ref-type="aff">16</xref>
                </contrib>
                <contrib id="author-31555896" contrib-type="author">
                  <name>
                    <surname>Austin</surname>
                    <given-names>Peter</given-names>
                  </name>
                  <xref rid="aff3" ref-type="aff">3</xref>
                  <xref rid="aff10" ref-type="aff">10</xref>
                </contrib>
                <contrib id="author-104104155" contrib-type="author">
                  <name>
                    <surname>Goldbloom</surname>
                    <given-names>Ellen</given-names>
                  </name>
                  <xref rid="aff17" ref-type="aff">17</xref>
                  <xref rid="aff18" ref-type="aff">18</xref>
                  <xref rid="aff19" ref-type="aff">19</xref>
                </contrib>
                <contrib id="author-52276681" contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-0102-2389</contrib-id>
                  <name>
                    <surname>Henderson</surname>
                    <given-names>MÃ©lanie</given-names>
                  </name>
                  <xref rid="aff20" ref-type="aff">20</xref>
                  <xref rid="aff21" ref-type="aff">21</xref>
                  <xref rid="aff22" ref-type="aff">22</xref>
                </contrib>
                <contrib id="author-104104183" contrib-type="author">
                  <name>
                    <surname>Landry</surname>
                    <given-names>Alanna</given-names>
                  </name>
                  <xref rid="aff23" ref-type="aff">23</xref>
                </contrib>
                <contrib id="author-58882144" contrib-type="author">
                  <name>
                    <surname>Zenlea</surname>
                    <given-names>Ian</given-names>
                  </name>
                  <xref rid="aff3" ref-type="aff">3</xref>
                  <xref rid="aff7" ref-type="aff">7</xref>
                  <xref rid="aff24" ref-type="aff">24</xref>
                </contrib>
                <contrib id="author-104104284" contrib-type="author">
                  <name>
                    <surname>Taylor</surname>
                    <given-names>Madison</given-names>
                  </name>
                  <xref rid="aff4" ref-type="aff">4</xref>
                </contrib>
                <contrib id="author-52595167" contrib-type="author">
                  <name>
                    <surname>Nakhla</surname>
                    <given-names>Meranda</given-names>
                  </name>
                  <xref rid="aff2" ref-type="aff">2</xref>
                </contrib>
                <contrib id="author-24379068" contrib-type="author" corresp="yes">
                  <name>
                    <surname>Shulman</surname>
                    <given-names>Rayzel</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">1</xref>
                  <xref rid="aff3" ref-type="aff">3</xref>
                  <xref rid="aff10" ref-type="aff">10</xref>
                  <xref rid="aff24" ref-type="aff">24</xref>
                  <xref rid="aff25" ref-type="aff">25</xref>
                </contrib>
              </contrib-group>
              <aff id="aff1"><label>1</label><institution specific-use="Ringgold_483367">SickKids Research Institute</institution>, <addr-line content-type="city">Toronto</addr-line>, <addr-line content-type="state">Ontario</addr-line>, <country>Canada</country></aff>
              <aff id="aff2"><label>2</label><institution>Research Institute of the McGill University Health Centre</institution>, <addr-line content-type="city">Montreal</addr-line>, <addr-line content-type="state">QC</addr-line>, <country>Canada</country></aff>
              <aff id="aff3"><label>3</label><institution content-type="department">Institute of Health Policy, Management and Evaluation</institution>, <institution>University of Toronto</institution>, <addr-line content-type="city">Toronto</addr-line>, <addr-line content-type="state">ON</addr-line>, <country>Canada</country></aff>
              <aff id="aff4"><label>4</label><institution content-type="department">Centre for Digital Therapeutics, Techna Institute</institution>, <institution>University Health Network</institution>, <addr-line content-type="city">Toronto</addr-line>, <addr-line content-type="state">ON</addr-line>, <country>Canada</country></aff>
              <aff id="aff5"><label>5</label><institution content-type="department">Institute of Biomaterials and Biomedical Engineering</institution>, <institution>University of Toronto</institution>, <addr-line content-type="city">Toronto</addr-line>, <addr-line content-type="state">ON</addr-line>, <country>Canada</country></aff>
              <aff id="aff6"><label>6</label><institution content-type="department">Department of Computer Science</institution>, <institution>University of Toronto</institution>, <addr-line content-type="city">Toronto</addr-line>, <addr-line content-type="state">ON</addr-line>, <country>Canada</country></aff>
              <aff id="aff7"><label>7</label><institution content-type="department">Institute for Better Health</institution>, <institution>Trillium Health Partners</institution>, <addr-line content-type="city">Mississauga</addr-line>, <addr-line content-type="state">ON</addr-line>, <country>Canada</country></aff>
              <aff id="aff8"><label>8</label><institution>Women's College Hospital Research Institute</institution>, <addr-line content-type="city">Toronto</addr-line>, <addr-line content-type="state">ON</addr-line>, <country>Canada</country></aff>
              <aff id="aff9"><label>9</label><institution content-type="department">School of Human Nutrition</institution>, <institution>McGill University</institution>, <addr-line content-type="city">Montreal</addr-line>, <addr-line content-type="state">QC</addr-line>, <country>Canada</country></aff>
              <aff id="aff10"><label>10</label><institution>ICES</institution>, <addr-line content-type="city">Toronto</addr-line>, <addr-line content-type="state">ON</addr-line>, <country>Canada</country></aff>
              <aff id="aff11"><label>11</label><institution content-type="department">Department of Medicine</institution>, <institution>University of Toronto</institution>, <addr-line content-type="city">Toronto</addr-line>, <addr-line content-type="state">ON</addr-line>, <country>Canada</country></aff>
              <aff id="aff12"><label>12</label><institution content-type="department">MAP Centre for Urban Health Solutions</institution>, <institution>Unity Health Toronto</institution>, <addr-line content-type="city">Toronto</addr-line>, <addr-line content-type="state">ON</addr-line>, <country>Canada</country></aff>
              <aff id="aff13"><label>13</label><institution content-type="department">Diabetes Action Canada</institution>, <institution>Canadian Institutes for Health Research (CIHR) Strategy for Patient-Oriented Research Network in Chronic Disease, Toronto General Hospital</institution>, <addr-line content-type="city">Toronto</addr-line>, <addr-line content-type="state">ON</addr-line>, <country>Canada</country></aff>
              <aff id="aff14"><label>14</label><institution content-type="department">Department of Philosophy, Joint Centre for Bioethics</institution>, <institution>University of Toronto</institution>, <addr-line content-type="city">Toronto</addr-line>, <addr-line content-type="state">ON</addr-line>, <country>Canada</country></aff>
              <aff id="aff15"><label>15</label><institution content-type="department">Department of Psychology</institution>, <institution>University of Windsor</institution>, <addr-line content-type="city">Windsor</addr-line>, <addr-line content-type="state">ON</addr-line>, <country>Canada</country></aff>
              <aff id="aff16"><label>16</label><institution content-type="department">Program for Health System and Technology Evaluation, Ted Rogers Centre for Heart Research</institution>, <institution>Toronto General Hospital Research Institute</institution>, <addr-line content-type="city">Toronto</addr-line>, <addr-line content-type="state">ON</addr-line>, <country>Canada</country></aff>
              <aff id="aff17"><label>17</label><institution content-type="department">Division of Endocrinology</institution>, <institution>Children's Hospital of Eastern Ontario</institution>, <addr-line content-type="city">Ottawa</addr-line>, <addr-line content-type="state">ON</addr-line>, <country>Canada</country></aff>
              <aff id="aff18"><label>18</label><institution>Children's Hospital of Eastern Ontario Research Institute</institution>, <addr-line content-type="city">Ottawa</addr-line>, <addr-line content-type="state">ON</addr-line>, <country>Canada</country></aff>
              <aff id="aff19"><label>19</label><institution content-type="department">Department of Pediatrics</institution>, <institution>University of Ottawa</institution>, <addr-line content-type="city">Ottawa</addr-line>, <addr-line content-type="state">ON</addr-line>, <country>Canada</country></aff>
              <aff id="aff20"><label>20</label><institution content-type="department">Department of Pediatrics</institution>, <institution>UniversitÃ© de MontrÃ©al</institution>, <addr-line content-type="city">Montreal</addr-line>, <addr-line content-type="state">QC</addr-line>, <country>Canada</country></aff>
              <aff id="aff21"><label>21</label><institution content-type="department">Centre de Resherche</institution>, <institution>CHU Sainte-Justine</institution>, <addr-line content-type="city">Montreal</addr-line>, <addr-line content-type="state">QC</addr-line>, <country>Canada</country></aff>
              <aff id="aff22"><label>22</label><institution content-type="department">School of Public Health, Department of Social and preventatitve Medicine</institution>, <institution>UniversitÃ© de MontrÃ©al</institution>, <addr-line content-type="city">Montreal</addr-line>, <addr-line content-type="state">QC</addr-line>, <country>Canada</country></aff>
              <aff id="aff23"><label>23</label><institution>Oak Valley Health</institution>, <addr-line content-type="city">Markham</addr-line>, <addr-line content-type="state">ON</addr-line>, <country>Canada</country></aff>
              <aff id="aff24"><label>24</label><institution content-type="department">Department of Pediatrics</institution>, <institution>University of Toronto</institution>, <addr-line content-type="city">Toronto</addr-line>, <addr-line content-type="state">ON</addr-line>, <country>Canada</country></aff>
              <aff id="aff25"><label>25</label><institution content-type="department">Division of Endocrinology</institution>, <institution>The Hospital for Sick Children</institution>, <addr-line content-type="city">Toronto</addr-line>, <addr-line content-type="state">ON</addr-line>, <country>Canada</country></aff>
              <author-notes>
                <corresp><label>Correspondence to</label> Dr Rayzel Shulman; <email>rayzel.shulman@sickkids.ca</email></corresp>
                <fn fn-type="other">
                  <p>MN and RS are joint senior authors.</p>
                </fn>
              </author-notes>
              <pub-date pub-type="collection">
                <year>2023</year>
              </pub-date>
              <pub-date pub-type="epub">
                <day>8</day>
                <month>5</month>
                <year>2023</year>
              </pub-date>
              <volume>13</volume>
              <issue>5</issue>
              <elocation-id>e071396</elocation-id>
              <history>
                <date date-type="received">
                  <day>28</day>
                  <month>12</month>
                  <year>2022</year>
                </date>
                <date date-type="accepted">
                  <day>18</day>
                  <month>4</month>
                  <year>2023</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>Â© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</copyright-statement>
                <copyright-year>2023</copyright-year>
                <ali:free_to_read/>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbynclicense" start_date="2023-05-08">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref>
                  <license-p>This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See:Â <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>.</license-p>
                </license>
              </permissions>
              <self-uri xlink:title="pdf" xlink:href="bmjopen-2022-071396.pdf"/>
              <self-uri content-type="reviewers-comments-pdf" xlink:href="bmjopen-2022-071396.reviewer_comments.pdf"/>
              <self-uri content-type="draft-revisions-pdf" xlink:href="bmjopen-2022-071396.draft_revisions.pdf"/>
              <abstract>
                <sec>
                  <title>Introduction</title>
                  <p>Transition from paediatric to adult care can be challenging for youth living with type 1 diabetes (T1D), as many youth feel unprepared to transfer to adult care and are at high risk for deterioration of glycaemic management and acute complications. Existing strategies to improve transition experience and outcomes are limited by cost, scalability, generalisability and youth engagement. Text messaging is an acceptable, accessible and cost-effective way of engaging youth. Together with adolescents and emerging adults and paediatric and adult T1D providers, we co-designed a text message-based intervention, Keeping in Touch (KiT), to deliver tailored transition support. Our primary objective is to test the effectiveness of KiT on diabetes self-efficacy in a randomised controlled trial.</p>
                </sec>
                <sec>
                  <title>Methods and analysis</title>
                  <p>We will randomise 183 adolescents with T1D aged 17â18 years within 4âmonths of their final paediatric diabetes visit to the intervention or usual care. KiT will deliver tailored T1D transition support via text messages over 12 months based on a transition readiness assessment. The primary outcome, self-efficacy for diabetes self-management, will be measured 12 months after enrolment. Secondary outcomes, measured at 6 and 12 months, include transition readiness, perceived T1D-related stigma, time between final paediatric and first adult diabetes visits, haemoglobin A1c, and other glycaemia measures (for continuous glucose monitor users), diabetes-related hospitalisations and emergency department visits and the cost of implementing the intervention. The analysis will be intention-to-treat comparing diabetes self-efficacy at 12 months between groups. A process evaluation will be conducted to identify elements of the intervention and individual-level factors influencing implementation and outcomes.</p>
                </sec>
                <sec>
                  <title>Ethics and dissemination</title>
                  <p>The study protocol version 7 July 2022 and accompanying documents were approved by Clinical Trials Ontario (Project ID: 3986) and the McGill University Health Centre (MP-37-2023-8823). Study findings will be presented at scientific conferences and in peer-reviewed publications.</p>
                </sec>
                <sec>
                  <title>Trial registration number</title>
                  <p><ext-link xlink:href="NCT05434754" ext-link-type="uri">NCT05434754</ext-link>.</p>
                </sec>
              </abstract>
              <kwd-group>
                <kwd>paediatric endocrinology</kwd>
                <kwd>telemedicine</kwd>
                <kwd>diabetes &amp; endocrinology</kwd>
                <kwd>clinical trials</kwd>
                <kwd>patient participation</kwd>
                <kwd>adolescent</kwd>
              </kwd-group>
              <funding-group specific-use="FundRef">
                <award-group id="funding-1">
                  <funding-source>
                    <institution-wrap>
                      <institution>Canadian Institutes of Health Research (CIHR)</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>423967</award-id>
                </award-group>
              </funding-group>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>special-feature</meta-name>
                  <meta-value>unlocked</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body>
            <boxed-text id="BX1" position="float">
              <caption>
                <title>Strengths and limitations of this study</title>
              </caption>
              <list list-type="bullet">
                <list-item>
                  <p>KiT was co-designed with people living with type 1 diabetes (T1D) and T1D care providers to ensure that it meets their needs and is acceptable. Our embedded process evaluation will inform real-time modifications to Keeping in Touch (KiT) early in the trial to enhance user engagement.</p>
                </list-item>
                <list-item>
                  <p>KiT uses text messages to deliver tailored T1D transition support based on participant-reported confidence about their diabetes-specific knowledge and skills.</p>
                </list-item>
                <list-item>
                  <p>The intervention will be tested in two provinces and offered in English and French.</p>
                </list-item>
                <list-item>
                  <p>KiT has the potential for scalability because most adolescents use mobile phones, and KiTâs text messages are delivered automatically via a computerised algorithm.</p>
                </list-item>
                <list-item>
                  <p>A limitation is that participants and investigators will be unblinded to their randomisation arm, given the nature of the intervention.</p>
                </list-item>
              </list>
            </boxed-text>
            <sec sec-type="intro" id="s1">
              <title>Introduction</title>
              <p>Type 1 diabetes (T1D) is one of the most common chronic diseases of childhood, with significant morbidity and mortality.<xref rid="R1" ref-type="bibr">1 2</xref> Maintaining optimal blood glucose levels prevents and delays long-term diabetes complications<xref rid="R3" ref-type="bibr">3</xref>; however, in-target glucose management is particularly challenging during adolescence and early adulthood alongside a myriad of emotional, physical, financial, occupational and social changes.<xref rid="R4" ref-type="bibr">4â6</xref> In Quebec and Ontario, Canada, adolescents transfer to adult healthcare at approximately the age of 18 years. There is also an increased risk of gaps in routine diabetes care as well as diabetes-related hospitalisations and emergency department visits during this time,<xref rid="R7" ref-type="bibr">7 8</xref> which may be due, in part, to deficiencies in transition care preparation.<xref rid="R9" ref-type="bibr">9â12</xref> Interventions to improve the transition from paediatric to adult T1D care are reported to improve clinic attendance, diabetes distress and satisfaction with care,<xref rid="R13" ref-type="bibr">13â16</xref> however, many interventions are limited by cost, scalability and generalisability.</p>
              <p>Two reviews of mobile phone technology, one to support adolescents with T1D and one to support the transition to adult care for all chronic conditions and for liver transplant recipients specifically, suggest that this technology can facilitate the delivery of educational material as well as encourage self-management and independence. However, the outcomes measured in these studies were varied (ie, haemoglobin A1c (HbA1c), quality of life and self-efficacy) and results were mixed.<xref rid="R17" ref-type="bibr">17 18</xref> These promising digital interventions may fail to engage youth across the transition period because they lack a personalised approach which precludes the ability to tailor content specific to an individualâs particular needs, stage of transition readiness or personal interests.<xref rid="R19" ref-type="bibr">19</xref> To date, most text message studies have described the use of simple reminders for self-care.<xref rid="R20" ref-type="bibr">20</xref> Text message-based interventions that rely on a healthcare provider to respond to messages are limited in their scalability.<xref rid="R21" ref-type="bibr">21</xref></p>
              <p>Nevertheless, general transition support delivered via text message is considered an engaging, acceptable, accessible and cost-effective option.<xref rid="R21" ref-type="bibr">21</xref> To address these limitations, together with youth, including adolescents and emerging adults living with T1D, and paediatric and adult T1D providers, we co-designed an automated text message-based intervention called Keeping in Touch (KiT) to deliver tailored T1D transition support messages in response to participantsâ self-reported confidence and interest in transition preparation topics. We hypothesise that compared with usual care, youth who use KiT for 12 months starting within 4âmonths before their final paediatric visit will have improved diabetes self-efficacy 12 months after enrolment.</p>
              <sec id="s1-1">
                <title>Objectives</title>
                <p>The primary objective of our study is to test the effectiveness of KiT, a text message-based T1D transition support intervention, on our primary outcome (diabetes self-efficacy) and secondary outcomes, including transition readiness, perceived T1D-related stigma, the time between final paediatric and first adult diabetes clinic visits, HbA1c, and other measures of glycaemia such as time in range (for those using continuous glucose monitors), and diabetes-related hospitalisations and emergency department visits. We will also conduct an embedded process evaluation to identify and understand which, if any, components of the intervention are associated with improved user engagement and individual-level contextual factors that influence the implementation process.</p>
              </sec>
            </sec>
            <sec sec-type="methods" id="s2">
              <title>Methods and analysis</title>
              <sec id="s2-1">
                <title>Study design</title>
                <p>We will conduct a multisite, parallel-group, two-arm, 1:1 allocation ratio, superiority randomised controlled trial (RCT). Our protocol adheres to the Standard Protocol Items for Randomised Trials (SPIRIT) statement. Considering the healthcare payer perspective, we will perform a descriptive cost analysis of the KiT implementation following Canadaâs Drug and Health Technology Agency (CADTH) guidelines and the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement.<xref rid="R22" ref-type="bibr">22 23</xref></p>
              </sec>
              <sec id="s2-2">
                <title>Study setting</title>
                <p>Our study will be conducted at six paediatric diabetes clinics; four in Ontario (two of which are located in academic tertiary-care hospitals (The Hospital for Sick Children and the Childrenâs Hospital of Eastern Ontario (CHEO)) and two in community clinics (Trillium Health Partners (THP) and Oak Valley Health (OVH)) and two clinics located in academic tertiary care paediatric hospitals in Quebec, Canada: Montreal Childrenâs Hospital, McGill University Health Centre (MUHC) and the Centre Hospitalier Universitaire Sainte-Justine (CHUSJ), University of MontrÃ©al. Recruitment started in January 2023 and will continue up until the end of June 2024. The intervention will end 12 months after recruitment is complete.</p>
              </sec>
              <sec id="s2-3">
                <title>Inclusion criteria</title>
                <p>Participants must be adolescents, living with T1D, be receiving care at one of the participating paediatric diabetes clinics, be within 4âmonths of their planned final paediatric clinic visit before transferring to adult diabetes care, be able to speak, understand and communicate in either English or French, have a mobile device with the capability to receive and send text messages, and a valid email address.</p>
              </sec>
              <sec id="s2-4">
                <title>Exclusion criteria</title>
                <p>Potential participants are ineligible if they are unable to carry out their diabetes care independently due to an intellectual or neurocognitive disability; are not a resident of Ontario or Quebec, Canada; are planning to change their primary residence out of either province within the upcoming 12 months; are enrolled in another clinical research trial that involves text messaging or any diabetes intervention trial that will continue beyond their planned final paediatric diabetes visit.</p>
              </sec>
              <sec id="s2-5">
                <title>Intervention</title>
                <p>The KiT algorithm is designed and programmed to send tailored T1D-related text messages at participant-determined frequencies over a 12-month intervention period. In a previous study, we scoped the needs of youth transitioning to adult care. In brief, we conducted interviews and co-design sessions with adolescents and young adults living with T1D and T1D care providers to determine how to optimally deliver transition support via text messages. Interview data analysis was grounded within the socioecological model and analysed using a thematic content approach.<xref rid="R24" ref-type="bibr">24 25</xref> KiT features, content topics and message formats were selected based on the themes and ideas that emerged in the co-design workshops and are supported in the literature. We validated and refined these through member-checking in co-design workshops.</p>
                <p>Research staff consent participants using site-specific version of ethics approved consent form KiT RCT_CTO_ICF_07JULY2022_CLEAN.docx (<xref rid="SP1" ref-type="supplementary-material">online supplemental material</xref>) virtually or in person. Participants randomised to the intervention arm will receive the KiT text message transition support programme for 12 months, hosted by Memotext, a company that provides a secure platform for digital patient engagement communications. Participants will have the option to use the programme in either English or French, the two official languages in Canada. Participants will have the option to pause the KiT messages at any time during the intervention. KiT has three key functions: (1) personalised T1D educational messages; (2) care coordination; and (3) question and answer (<xref rid="T1" ref-type="table">table 1</xref>). KiT will only delivery text messages to the participant themselves, however, the participant may share any of the text messages with their support network.</p>
                <supplementary-material id="SP1" position="float" content-type="local-data">
                  <object-id pub-id-type="doi">10.1136/bmjopen-2022-071396.supp1</object-id>
                  <label>Supplementary data</label>
                  <p>
                    <inline-supplementary-material id="SS1" xlink:href="bmjopen-2022-071396supp001.pdf" content-type="local-data"/>
                  </p>
                </supplementary-material>
                <table-wrap position="float" id="T1">
                  <label>Table 1</label>
                  <caption>
                    <p>KiT functions and example text messages</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <thead>
                      <tr>
                        <td align="left" valign="bottom" rowspan="1" colspan="1">Feature category</td>
                        <td align="left" valign="bottom" rowspan="1" colspan="1">Intervention feature</td>
                        <td align="left" valign="bottom" rowspan="1" colspan="1">Sample dialogue</td>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Personalised T1D educational messages</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <list list-type="bullet">
                            <list-item>
                              <p>Participants will receive multiple messages each month about a different T1D transition topic.</p>
                            </list-item>
                            <list-item>
                              <p>Topics will be selected based on the participantâs responses to a transition readiness assessment administered at baseline and topics of their choice.</p>
                            </list-item>
                          </list>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">KiT: When you travelâbe sure to pack LOTS of extra supplies for a stress-free trip! You can pack extra: glucose metres, batteries, pumps and infusion sets (some pump companies will give you a travel loaner pump for free!), insulin and syringes (in case your pump malfunctions), test strips and medications. Itâs good to have these on hand, just in case.<break/>This video is a great example of some things you might want to (over) pack (link to TikTok video)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Care coordination</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <list list-type="bullet">
                            <list-item>
                              <p>Reminders about upcoming appointments.</p>
                            </list-item>
                            <list-item>
                              <p>Reminders to complete lab tests before upcoming appointments (if applicable).</p>
                            </list-item>
                            <list-item>
                              <p>Information about participantâs adult clinic (if available).</p>
                            </list-item>
                            <list-item>
                              <p>Tips about how to prepare for the first adult visit.</p>
                            </list-item>
                            <list-item>
                              <p>Participants can store their own notes, which they can access any time and will be sent back to the participant automatically before an upcoming clinic visit.</p>
                            </list-item>
                          </list>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">KiT: Hello! Do you know when your next appointment is?<break/>User: It is on 27 September 2022 at 14:00 hours<break/>KiT: Perfect, Iâll send you a reminder the week before so you donât forget!</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Question and answer</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <list list-type="bullet">
                            <list-item>
                              <p>Participant can text KiT T1D-related questions and receive messages in return from a validated bank of resources.</p>
                            </list-item>
                          </list>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">User: How can I adjust my insulin so I donât go low when I exercise?<break/>KiT: Thanks for asking! Hopefully this resource about insulin and exercise from ExCarbs answers your question (link to resource website)</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <fn id="T1_FN1">
                      <p>KiT, Keeping in Touch; T1D, type 1 diabetes.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <list list-type="order">
                  <list-item>
                    <p>T1D educational messages: KiT will send text messages about T1D-related transition preparation topics. Core topics will be sent to all participants. Other topics will be delivered based on participantsâ self-reported confidence and interest in the topics. This will be based, in part, on responses to a validated transition readiness tool administered at baseline (described in the outcome section below): Readiness Assessment of Emerging Adults with Type 1 Diabetes Diagnosed in Youth (READDY) tool.<xref rid="R26" ref-type="bibr">26</xref> Some messages include text only, previously developed during the co-design process, with input from T1D providers and people living with T1D. Some messages include a link to a trusted T1D resource identified in our environmental scan of online educational resources for youth with T1D transitioning to adult care.<xref rid="R27" ref-type="bibr">27</xref> A list of education content topics is available in <xref rid="B1" ref-type="boxed-text">box 1</xref>.</p>
                  </list-item>
                </list>
                <boxed-text id="B1" position="float">
                  <label>Box 1</label>
                  <caption>
                    <title>T1D related-transition educational content topics</title>
                  </caption>
                  <sec>
                    <title>Topics delivered to all participants in the intervention group</title>
                    <p>Coping with T1D</p>
                    <p>Care navigation</p>
                    <p>Sick day and ketone management</p>
                    <p>Medical insurance</p>
                  </sec>
                  <sec>
                    <title>Topics delivered based on participantsâ self-reported confidence and interest</title>
                    <p>Hypoglycaemia</p>
                    <p>Pumps and programming</p>
                    <p>Insulin adjustments</p>
                    <p>Drugs and alcohol</p>
                    <p>Travel</p>
                    <p>Driving</p>
                    <p>T1D accommodations for school and work</p>
                    <p>Exercise</p>
                    <p>Nutrition and carbohydrates</p>
                    <p>Sexual health</p>
                  </sec>
                </boxed-text>
                <list list-type="order">
                  <list-item>
                    <p>Care coordination: on enrolment and throughout the intervention, KiT will send participants text messages asking if, and when, they have upcoming appointments with their diabetes clinics. KiT will store this information and send participants text message reminders about upcoming visits and information related to transition to adult diabetes care, such as preparing for upcoming clinic appointments. In addition, KiT will send reminders to participants to book appointments and prompt those who have not yet been referred to adult care to follow-up with their paediatric care team for a referral. KiT will remind participants about the importance of having a primary care provider and send links to online services that can help them find one, if needed.</p>
                  </list-item>
                  <list-item>
                    <p>Question and answer: participants can send text messages asking KiT about topics related to T1D care at any time during the intervention. KiT will match keywords in the question to trusted resources identified in the environmental scan of online educational resources and reply to participants with a text message and a link to a relevant T1D transition resource, if available.</p>
                    <p>Participants randomised to the control arm will receive usual diabetes transition care and text messages from KiT containing links to the outcome surveys over 12 months.</p>
                  </list-item>
                </list>
              </sec>
              <sec id="s2-6">
                <title>Recruitment</title>
                <p>Participants will be recruited over 18 months. We will have poster advertisements in clinic waiting areas. A member of the circle of care will provide a study information letter and introduce a study research coordinator to potential participants. Participants in both arms will receive gift cards as a token of appreciation for their time participating in the study. Recruitment targets are feasible based on six diabetes clinic volumes and experience from recent transition-related studies. Local site coordinators will obtain informed consent.</p>
              </sec>
              <sec id="s2-7">
                <title>Randomisation</title>
                <p>The allocation sequence will be computer generated using random block sizes by an independent statistician using a 1:1 ratio, stratified by site, at the time of enrolment. Due to the nature of the intervention, participants and investigators cannot be blinded to group allocation. We will conceal random allocation from the independent statistician assigning participants to the interventions and those analysing the data.</p>
              </sec>
              <sec id="s2-8">
                <title>Data collection</title>
                <p>At the time of enrolment, research coordinators will collect each participantâs postal code to be linked to an area-based validated material and social deprivation index as a measure of socioeconomic status.<xref rid="R28" ref-type="bibr">28 29</xref> The coordinator will also collect the most recent HbA1c result (either laboratory or point-of-care) from the health record to measure baseline glycaemic management. There is a standardised method for measuring HbA1c.<xref rid="R30" ref-type="bibr">30</xref> All participants, in both arms, will receive a text message at the time of enrolment, 6 months and at 12 months containing a link to REDCap surveys for assessment of outcomes. The surveys include a participant information survey, which will collect sociodemographic and diabetes-related healthcare information (<xref rid="SP2" ref-type="supplementary-material">online supplemental table 1</xref>), and three patient-reported outcome measures.</p>
                <supplementary-material id="SP2" position="float" content-type="local-data">
                  <object-id pub-id-type="doi">10.1136/bmjopen-2022-071396.supp2</object-id>
                  <label>Supplementary data</label>
                  <p>
                    <inline-supplementary-material id="SS2" xlink:href="bmjopen-2022-071396supp002.pdf" content-type="local-data"/>
                  </p>
                </supplementary-material>
                <p>Text-message records between KiT and participants will be saved on a secure encrypted server at Memotext. We will also collect participantsâ provincial health insurance numbers to link to provincial administrative datasets housed at ICES in Ontario and RÃ©gie de l'assurance maladie du QuÃ©bec (RAMQ) in Quebec. Site coordinators will assign unique study IDs for each participant. Each study ID will be linked to a unique survey code. All survey responses are collected and securely stored in REDCap. <xref rid="T2" ref-type="table">Table 2</xref> shows the primary and secondary outcomes and when they are each collected.</p>
                <table-wrap position="float" id="T2">
                  <label>Table 2</label>
                  <caption>
                    <p>Primary and secondary outcomes and time of collection</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <thead>
                      <tr>
                        <td align="left" valign="bottom" rowspan="1" colspan="1">Outcome</td>
                        <td align="left" valign="bottom" rowspan="1" colspan="1">Baseline (time of enrolment)</td>
                        <td align="left" valign="bottom" rowspan="1" colspan="1">6 months</td>
                        <td align="left" valign="bottom" rowspan="1" colspan="1">12 months</td>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="4">Chart abstraction</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"><named-content content-type="indent">â</named-content>HbA1c (laboratory or point-of-care)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="4">Survey</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"><named-content content-type="indent">â</named-content>Self-Efficacy for Diabetes Self-Management (SEDM)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"><named-content content-type="indent">â</named-content>Transition Readiness Assessment for Emerging Adults with Diabetes Diagnosed in Youth (READDY)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"><named-content content-type="indent">â</named-content>Barriers to Diabetes Adherence (BDA) in Adolescence questionnaire Stigma subscale</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"><named-content content-type="indent">â</named-content>Self-reported HbA1c</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"><named-content content-type="indent">â</named-content>Self-reported measures of glycaemia (participants using continuous glucose monitors): time in range and time in âlowâ</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"><named-content content-type="indent">â</named-content>Date of final paediatric visit</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">x (if not provided at baseline)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">x (if not provided at baseline)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"><named-content content-type="indent">â</named-content>Date of first adult visit</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">x (if final paediatric visit has occurred)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">x (if final paediatric visit has occurred and not previously reported)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">x (if final paediatric visit has occurred and not previously reported)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Administrative data</td>
                        <td align="left" valign="top" rowspan="1" colspan="3"/>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"><named-content content-type="indent">â</named-content>Diabetes-related hospitalisations</td>
                        <td align="left" valign="top" rowspan="2" colspan="3">12 months prior to enrolment and 12 months from the time of enrolment</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"><named-content content-type="indent">â</named-content>Diabetes-related emergency department visits</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <fn id="T2_FN1">
                      <p>HbA1C, haemoglobin A1c; T1D, type 1 diabetes.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec id="s2-9">
                <title>Outcomes</title>
                <sec id="s2-9-1">
                  <title>Primary outcome</title>
                  <p>The primary outcome is patient-reported diabetes self-efficacy at 12 months measured using the Self-Efficacy for Diabetes Self-Management (SEDM) scale. Self-efficacy measures a personâs belief that they can carry out a behaviour in a particular situation.<xref rid="R31" ref-type="bibr">31</xref> Self-efficacy is associated with health-related outcomes.<xref rid="R32" ref-type="bibr">32</xref> The SEDM scale has been validated in adolescents with T1D and found to be associated with diabetes self-management and glycaemic management in older adolescents.<xref rid="R33" ref-type="bibr">33</xref></p>
                </sec>
                <sec id="s2-9-2">
                  <title>Secondary outcomes</title>
                  <p>Secondary outcomes will be measured at baseline, 6 months and 12 months. <xref rid="T2" ref-type="table">Table 2</xref> lists all the outcomes, the data source, and when they will be collected.</p>
                  <list list-type="order">
                    <list-item>
                      <p>Diabetes self-efficacy</p>
                    </list-item>
                    <list-item>
                      <p>Transition readiness</p>
                    </list-item>
                    <list-item>
                      <p>Diabetes-related stigma</p>
                    </list-item>
                    <list-item>
                      <p>Glycaemic management</p>
                    </list-item>
                    <list-item>
                      <p>The time between the final paediatric and first adult diabetes visits (calculated from the self-reported date of the final paediatric and first adult visit)</p>
                    </list-item>
                    <list-item>
                      <p>Diabetes-related hospitalisations and emergency department visits</p>
                    </list-item>
                    <list-item>
                      <p>Cost of implementation (aggregate cost of implementation and cost per participant)</p>
                    </list-item>
                  </list>
                  <sec id="s2-9-2-1">
                    <title>Patient-reported outcomes</title>
                    <p>Patient-reported outcomes will be collected in electronic surveys sent to participants via a link in a text message at baseline, 6 months and 12 months. Up to two automatic reminder messages will be sent via text message if a survey is not completed. If a survey still needs to be completed after two text message reminders, the research coordinator will contact the participant to remind them to complete the survey.</p>
                    <p>We will measure transition readiness using the Readiness Assessment of Emerging Adults with Type 1 Diabetes Diagnosed in Youth (READYY) tool.<xref rid="R26" ref-type="bibr">26</xref> READDY is a transition readiness assessment for emerging adults with diabetes that asks about self-reported confidence in five domains: diabetes knowledge, health system navigation, insulin self-management, health behaviours and insulin pump skills (optional). Diabetes-related stigma will be measured using the Barriers to Diabetes Adherence in Adolescence (BDA) questionnaire Stigma subscale.<xref rid="R34" ref-type="bibr">34</xref> Additional details about the patient-reported outcome measures are presented in <xref rid="T3" ref-type="table">table 3</xref>.</p>
                    <table-wrap position="float" id="T3">
                      <label>Table 3</label>
                      <caption>
                        <p>Description of the patient-reported outcome measures</p>
                      </caption>
                      <table frame="hsides" rules="groups">
                        <thead>
                          <tr>
                            <td align="left" valign="bottom" rowspan="1" colspan="1">Questionnaire</td>
                            <td align="left" valign="bottom" rowspan="1" colspan="1">Details</td>
                            <td align="left" valign="bottom" rowspan="1" colspan="1">Validity/reliability</td>
                          </tr>
                        </thead>
                        <tbody>
                          <tr>
                            <td align="left" valign="top" rowspan="1" colspan="1">Self-efficacy (Self-Efficacy for diabetes Self-Management Measure)</td>
                            <td align="left" valign="top" rowspan="1" colspan="1">Respondents report their certainty in their ability to carry out 10 specific diabetes self-management tasks almost all of the time on a 10-point Likert scale from 1 ânot at all sureâ to 10 âcompletely sureâ.</td>
                            <td align="left" valign="top" rowspan="1" colspan="1">Validated and reliable in adolescents with T1D (Î±=0.90); shown to have good internal consistency and test-retest validity.<xref rid="R33" ref-type="bibr">33</xref></td>
                          </tr>
                          <tr>
                            <td align="left" valign="top" rowspan="1" colspan="1">READDY (transition readiness assessment for emerging adults with diabetes diagnosed in youth)</td>
                            <td align="left" valign="top" rowspan="1" colspan="1">Respondents answer on a 5-point Likert scale from âyes, I can do thisâ to âHavenât thought about itâ for 42 items, split into five domains: diabetes knowledge, health system navigation, insulin self-management, health behaviours and insulin pump skills (optional).</td>
                            <td align="left" valign="top" rowspan="1" colspan="1">Validated during its development by examining its correlation with existing validated transition readiness tools.<xref rid="R26" ref-type="bibr">26</xref></td>
                          </tr>
                          <tr>
                            <td align="left" valign="top" rowspan="1" colspan="1">BDA (Barriers to Diabetes Adherence) in Adolescence questionnaire Stigma Subscale</td>
                            <td align="left" valign="top" rowspan="1" colspan="1">Stigma will be defined as an affirmative response to at least one of three key items on this subscale.</td>
                            <td align="left" valign="top" rowspan="1" colspan="1">the Barriers to Diabetes Adherence in Adolescence questionnaire was developed to measure psychosocial barriers to adherence in adolescents with T1D; the stigma subscale has previously shown to be useful in research and clinical settings.<xref rid="R34" ref-type="bibr">34</xref></td>
                          </tr>
                        </tbody>
                      </table>
                      <table-wrap-foot>
                        <fn id="T3_FN1">
                          <p>T1D, type 1 diabetes.</p>
                        </fn>
                      </table-wrap-foot>
                    </table-wrap>
                  </sec>
                  <sec id="s2-9-2-2">
                    <title>Glycaemic management</title>
                    <p>We will collect the most recent HbA1c in the chart at baseline (either lab or point-of-care). We will also collect self-reported HbA1c and other measures of glycaemia (time in range and percent of time in âlowâ for participants who report using a continuous glucose monitor for at least 80% of the time in the preceding 14 days) at baseline, 6 months, and 12 months.</p>
                  </sec>
                  <sec id="s2-9-2-3">
                    <title>Diabetes-related hospitalisations and emergency department visits</title>
                    <p>We will securely link participantsâ provincial health card numbers to provincial administrative databases housed at ICES in Ontario and Med-Echo and RÃ©gie de l'assurance maladie du QuÃ©bec (RAMQ) in Quebec. We will measure all diabetes-related hospitalisations and emergency department visits during the 12 months before enrolment in the study and for 12 months after enrolment. In Ontario, we will ascertain all diabetes-related hospitalisations from the Canadian Institute of Health Information discharge abstract database, and diabetes-related emergency department visits will be ascertained using the National Ambulatory Clinic Reporting System. In Quebec, we will ascertain diabetes-related hospitalisations from Med-Echo (hospitalisations), and diabetes-related emergency department visits will be identified from the RAMQ databases. Diabetes-related emergency department visits will be identified as those with a diagnosis code for hyperglycaemia (ICD-9 code 250) and hypoglycaemia (ICD-9 code 251). Diabetes-related hospitalisations will be identified as those diagnosed with hyperglycaemia (ICD-10 codes E10.0âE14.0 and E10.1âE14.1), including diabetic ketoacidosis and hyperosmolar hyperglycaemic coma and those with a diagnosis of hypoglycaemia (E10.63âE14.63).</p>
                  </sec>
                  <sec id="s2-9-2-4">
                    <title>Cost of implementation</title>
                    <p>We will determine the cost of adapting and implementing the intervention in an outpatient paediatric diabetes clinic in Ontario and Quebec. We will consider the costs of adapting the algorithm, salary support for staff to enrol participants, digital services and office equipment to host the intervention (computers, hosting service, servers). Specifically, we will measure the following: (1) labour costs, including staff salaries; (2) infrastructure and equipment costs; and 3) administrative and operating costs. Cost data will come directly from the programme, which will provide detailed information on all costs.</p>
                  </sec>
                </sec>
              </sec>
              <sec id="s2-10">
                <title>Sample size</title>
                <p>Assuming a SD of 1.6 for the self-efficacy score<xref rid="R33" ref-type="bibr">33</xref> and 6 degrees of freedom for adjustment (1 for HbA1c, 1 for the baseline value of the outcome variable and 4 for the 5 quintiles of deprivation), we require a total sample size of 183 participants to have 80% power with Î±=0.05, allowing for 20% dropout. This assumes that the covariates used for adjustment explain 10% of the variation in the outcome. Given the absence of published data to inform this quantity, we have opted to be conservative and assume a low R<sup>2</sup>, which will require a larger sample size rather than assuming a high value of R<sup>2</sup>.</p>
              </sec>
              <sec id="s2-11">
                <title>Statistical analysis</title>
                <p>We will conduct an intention-to-treat analysis. We will conduct a secondary as-treated analysis including participants who engaged with KiT (did not have any message delivery failures) stratified by engagement level. Engagement level will be defined according to the intervention usage data during the 12-month intervention period; this approach has been used in prior studies.<xref rid="R35" ref-type="bibr">35</xref></p>
                <p>We will compare the primary outcome, diabetes self-efficacy score at 12 months, between groups. This will be done using analysis of covariance (ANCOVA) to compare the effect of the intervention between arms. We will include the following covariates: intervention arm, baseline diabetes self-efficacy score (to reduce possible residual imbalance between groups), baseline HbA1c (known to be associated with diabetes self-efficacy),<xref rid="R33" ref-type="bibr">33</xref> and material deprivation quintile (socioeconomic status is known to be associated with T1D care and outcomes).<xref rid="R36" ref-type="bibr">36</xref> To compare secondary outcomes between arms at 6 and 12 months, we will use ANCOVA and logistic regression models for continuous and binary outcomes respectively. We will include the following covariates in each of these models: intervention arm, the baseline measure of the outcome of interest (if measured and when the outcome is continuous), baseline HbA1c and material deprivation. We will conduct a secondary analysis to calculate within-arm differences in outcomes at baseline, 6 months and 12 months. For the within-arm analyses, we will use the appropriate paired test (either the paired t-test or McNemarâs test) to account for the repeated measurements on each subject.</p>
                <p>For the descriptive cost analysis of the KiT implementation, we will calculate the aggregate cost of implementation and cost per participant. The costs will be reported in 2024 Canadian Dollars, adjusted for inflation using the Bank of Canada inflation calculator.<xref rid="R37" ref-type="bibr">37</xref> When relevant, we will consider a 1.5% discount rate for cost and health outcomes per the Canadian Guidelines for Economic Evaluations.</p>
              </sec>
              <sec id="s2-12">
                <title>Harms</title>
                <p>We do not expect adverse or serious adverse events related to the intervention to occur due to the nature of the intervention. Common words associated with high-risk behaviours (eg, suicide) will also be matched, and appropriate support resources will be provided to participants. Participants will have the option to pause the KiT messages at any time during the intervention. Any elevated harm, discomfort or distress experienced by the participants and communicated to the research team will be immediately reported to the principal investigators and the Research Ethics Board.</p>
              </sec>
              <sec id="s2-13">
                <title>Patient and public involvement</title>
                <p>The KiT intervention was created by a co-design process including people living with T1D and T1D providers.<xref rid="R38" ref-type="bibr">38</xref> Our research team also includes a patient partner (co-principal investigator) who contributed to the study design and will continue to provide input during the implementation and evaluation phases of the RCT.</p>
              </sec>
              <sec id="s2-14">
                <title>Data management</title>
                <p>All participants will be assigned a study ID number. Only study team members can access the code linking the participantâs name to the study file. On randomisation, the research coordinator will securely send Memotext the randomised participant study ID, randomisation arm and mobile phone number. KiT will send a text message to the participantâs mobile phone introducing them to the study and send links to complete the study surveys on SickKids external REDCap (for both arms). The REDCap Application Programming Interface integration enables SickKids REDCap servers to deploy chatbot links for REDCap surveys. User engagement data will be stored on the secure servers of Memotext, located in Toronto. Memotext collects and uses data in accordance with all applicable laws and PIPEDA and HIPAA.</p>
              </sec>
            </sec>
            <sec sec-type="discussion" id="s3">
              <title>Discussion</title>
              <p>A strength of our study is that the intervention, KiT, was co-designed with people living with T1D and T1D providers to ensure that it meets their needs and is acceptable. It also addresses important limitations of previous transition interventions by delivering tailored transition education and support based on participant-reported confidence about diabetes-specific knowledge, skills and topics selected based on interest rather than a one-size-fits-all approach. Further, the intervention will be delivered entirely via text messages, a modality with proven accessibility that is easily scalable since 97.9% of Canadians aged 15â24 years have access to a smartphone.<xref rid="R39" ref-type="bibr">39</xref> Since we are testing KiT in two provinces and two languages, we will be able to evaluate its effectiveness in different contexts. A limitation is that participants and investigators will be unblinded to their randomisation arm, given the nature of the intervention components.</p>
              <p>Our findings will inform the field of digital health by testing an intervention delivered entirely by text messages. Further, our findings will add to the literature about the effectiveness of interventions for transition to adult diabetes care without the need for healthcare provider support. Next steps are to assess the cost effectiveness of the intervention and to consider opportunities to scale KiT and to adapt it for other childhood chronic illnesses.</p>
            </sec>
            <sec id="s4">
              <title>Ethics and dissemination</title>
              <p>We have research ethics board approvals at the provincial level from Clinical Trials Ontario (CTO) and centre-level approvals from research ethics boards at all four Ontario sites (The Hospital for Sick Children, the Childrenâs Hospital of Eastern Ontario (CHEO), Trillium Health Partners (THP) and Oak Valley Health (OVH). We have received research ethics board approval from the McGill University Health Centre (MUHC) REB. In Quebec, there is a central ethics approval process for multisite studies. Protocol amendments (eg, changes to eligibility criteria, outcomes or analyses) will be submitted to the Research Ethics Boards. Important protocol modifications will be communicated to investigators, trial participants, and the ClinicalTrials.gov registry.</p>
              <p>We plan to present the findings of this study at scientific conferences and in peer-reviewed publications. We plan to disseminate our findings through diabetes organisations with whom we have engaged since this studyâs inception, including Diabetes Action Canada, the Ontario Paediatric Diabetes Network and Foundation Ressources Pour Nos Enfants DiabÃ©tiques (FRED). If KiT is effective, we will engage with the Canadian Pediatric Diabetes Consortium (CAPACIty) to explore opportunities to scale and expand its use.</p>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Supplementary Material</title>
              <supplementary-material content-type="local-data" id="d64e559">
                <caption>
                  <title>Reviewer comments</title>
                </caption>
                <media xlink:href="bmjopen-2022-071396.reviewer_comments.pdf"/>
              </supplementary-material>
              <supplementary-material content-type="local-data" id="d64e560">
                <caption>
                  <title>Author's
manuscript</title>
                </caption>
                <media xlink:href="bmjopen-2022-071396.draft_revisions.pdf"/>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ack>
              <p>We would like to acknowledge the contribution of the Patient Partners involved in this research project as well as the facilitation provided by Diabetes Action Canada, a Canadian Institutes for Health Research (CIHR) Strategy for Patient-Oriented Research Network in Knowledge Mobilization and Implementation Science.</p>
              <p>We would also like to acknowledge Noor El- Dassouki, Research Associate, UHN for her contribution to the development of KiT and editing the manuscript</p>
            </ack>
            <fn-group>
              <fn fn-type="other">
                <p><bold>Twitter:</bold> @lauradesveaux</p>
              </fn>
              <fn fn-type="other">
                <p><bold>Correction notice:</bold> The acknowledgement section in the article is updated since it was first published.</p>
              </fn>
              <fn fn-type="other">
                <p><bold>Contributors:</bold> RS and MN designed the study. Other authors EM, JAC, LD, A-SB, GLB, MG, JK, VER, PA, EG, MH, AL, IZ and MT contributed to the design of the study. GS prepared the initial draft of the manuscript. All authors provided feedback and approved the final manuscript.</p>
              </fn>
              <fn fn-type="other">
                <p><bold>Funding:</bold> This work was supported by a Canadian Institutes of Health Research (CIHR) Team grant: Transitions in Care. Application number 423967.</p>
              </fn>
              <fn fn-type="COI-statement">
                <p><bold>Competing interests:</bold> RS and A-SB have received speaking fees from Dexcom. EG is the Site Co-Investigator role for Medtronic study grant to the institution and Chair of EpicÂ® Pediatric Endocrinology Specialty Steering Board. IZ reports receiving personal fees from Abbott Diabetes Care and Novo Nordisk Canada Inc. and research funding support from the University of Toronto, Navigator Limited, the Medical Psychiatry Alliance, Regional Municipality of Peel, Community Foundation of Mississauga, Canadian Institutes of Health Research (CIHR), and Social Sciences and Humanities Research Council of Canada (SSHRC). MH is recipient of the 2019 Canadian Society of Endocrinology and Metabolismâs Young Investigator Award, and a FRQS Senior salary award. Her research has been funded by the Canadian Institutes of Health Research (CIHR), Heart and Stroke Foundation of Canada, DiabÃ¨te QuÃ©bec and Fonds de recherche en SantÃ© du quÃ©bec (FRQS).</p>
              </fn>
              <fn fn-type="other">
                <p><bold>Patient and public involvement:</bold> Patients and/or the public were involved in the design, or conduct, or reporting or dissemination plans of this research. Refer to the Methods section for further details.</p>
              </fn>
              <fn fn-type="other">
                <p><bold>Provenance and peer review:</bold> Not commissioned; peer reviewed for ethical and funding approval prior to submission.</p>
              </fn>
              <fn fn-type="other">
                <p><bold>Supplemental material:</bold> This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.</p>
              </fn>
            </fn-group>
            <sec sec-type="ethics-statement">
              <title>Ethics statements</title>
              <sec>
                <title>Patient consent for publication</title>
                <p content-type="ethics-consent-to-publish">Not applicable.</p>
              </sec>
            </sec>
            <ref-list>
              <title>References</title>
              <ref id="R1">
                <label>1</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ward</surname><given-names>ZJ</given-names></string-name>, <string-name><surname>Yeh</surname><given-names>JM</given-names></string-name>, <string-name><surname>Reddy</surname><given-names>CL</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Estimating the total incidence of type 1 diabetes in children and adolescents aged 0â19 years from 1990 to 2050: a global simulation-based analysis</article-title>. <source>The Lancet Diabetes &amp; Endocrinology</source><year>2022</year>;<volume>10</volume>:<fpage>848</fpage>â<lpage>58</lpage>. <pub-id pub-id-type="doi">10.1016/S2213-8587(22)00276-5</pub-id><pub-id pub-id-type="pmid">36372070</pub-id></mixed-citation>
              </ref>
              <ref id="R2">
                <label>2</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gregory</surname><given-names>GA</given-names></string-name>, <string-name><surname>Robinson</surname><given-names>TIG</given-names></string-name>, <string-name><surname>Linklater</surname><given-names>SE</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Global incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040: a modelling study</article-title>. <source>Lancet Diabetes Endocrinol</source><year>2022</year>;<volume>10</volume>:<fpage>741</fpage>â<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1016/S2213-8587(22)00218-2</pub-id><pub-id pub-id-type="pmid">36113507</pub-id></mixed-citation>
              </ref>
              <ref id="R3">
                <label>3</label>
                <mixed-citation publication-type="journal"><article-title>Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: diabetes control and complications trial</article-title>. <source>J Pediatr</source><year>1994</year>;<volume>125</volume>:<fpage>177</fpage>â<lpage>88</lpage>. <pub-id pub-id-type="doi">10.1016/S0022-3476(94)70190-3</pub-id><pub-id pub-id-type="pmid">8040759</pub-id></mixed-citation>
              </ref>
              <ref id="R4">
                <label>4</label>
                <mixed-citation publication-type="other"><person-group person-group-type="author"><collab>Canadian Association of Paediatric Health Centres</collab></person-group>. <article-title>A guideline for transition from paediatric to adult health care for youth with special health care needs: a national approach</article-title>; <year>2016</year>.</mixed-citation>
              </ref>
              <ref id="R5">
                <label>5</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Arnett</surname><given-names>JJ</given-names></string-name></person-group>. <article-title>Emerging adulthood. A theory of development from the late teens through the twenties</article-title>. <source>Am Psychol</source><year>2000</year>;<volume>55</volume>:<fpage>469</fpage>â<lpage>80</lpage>. <pub-id pub-id-type="doi">10.1037//0003-066X.55.5.469</pub-id><pub-id pub-id-type="pmid">10842426</pub-id></mixed-citation>
              </ref>
              <ref id="R6">
                <label>6</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wafa</surname><given-names>S</given-names></string-name>, <string-name><surname>Nakhla</surname><given-names>M</given-names></string-name></person-group>. <article-title>Improving the transition from pediatric to adult diabetes healthcare: a literature review</article-title>. <source>Can J Diabetes</source><year>2015</year>;<volume>39</volume>:<fpage>520</fpage>â<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.jcjd.2015.08.003</pub-id><pub-id pub-id-type="pmid">26498219</pub-id></mixed-citation>
              </ref>
              <ref id="R7">
                <label>7</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Shulman</surname><given-names>R</given-names></string-name>, <string-name><surname>Shah</surname><given-names>BR</given-names></string-name>, <string-name><surname>Fu</surname><given-names>L</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Diabetes transition care and adverse events: a population-based cohort study in Ontario, Canada</article-title>. <source>Diabet Med</source><year>2018</year>;<volume>35</volume>:<fpage>1515</fpage>â<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1111/dme.13782</pub-id><pub-id pub-id-type="pmid">30022524</pub-id></mixed-citation>
              </ref>
              <ref id="R8">
                <label>8</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Nakhla</surname><given-names>M</given-names></string-name>, <string-name><surname>Daneman</surname><given-names>D</given-names></string-name>, <string-name><surname>To</surname><given-names>T</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Transition to adult care for youths with diabetes mellitus: findings from a universal health care system</article-title>. <source>Pediatrics</source><year>2009</year>;<volume>124</volume>:<fpage>e1134</fpage>â<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1542/peds.2009-0041</pub-id><pub-id pub-id-type="pmid">19933731</pub-id></mixed-citation>
              </ref>
              <ref id="R9">
                <label>9</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Garvey</surname><given-names>KC</given-names></string-name>, <string-name><surname>Wolpert</surname><given-names>HA</given-names></string-name>, <string-name><surname>Rhodes</surname><given-names>ET</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Health care transition in patients with type 1 diabetes: young adult experiences and relationship to glycemic control</article-title>. <source>Diabetes Care</source><year>2012</year>;<volume>35</volume>:<fpage>1716</fpage>â<lpage>22</lpage>. <pub-id pub-id-type="doi">10.2337/dc11-2434</pub-id><pub-id pub-id-type="pmid">22699289</pub-id></mixed-citation>
              </ref>
              <ref id="R10">
                <label>10</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lotstein</surname><given-names>DS</given-names></string-name>, <string-name><surname>Seid</surname><given-names>M</given-names></string-name>, <string-name><surname>Klingensmith</surname><given-names>G</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Transition from pediatric to adult care for youth diagnosed with type 1 diabetes in adolescence</article-title>. <source>Pediatrics</source><year>2013</year>;<volume>131</volume>:<fpage>e1062</fpage>â<lpage>70</lpage>. <pub-id pub-id-type="doi">10.1542/peds.2012-1450</pub-id><pub-id pub-id-type="pmid">23530167</pub-id></mixed-citation>
              </ref>
              <ref id="R11">
                <label>11</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pacaud</surname><given-names>D</given-names></string-name>, <string-name><surname>Yale</surname><given-names>JF</given-names></string-name>, <string-name><surname>Stephure</surname><given-names>D</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Problems in transition from pediatric care to adult care for individuals with diabetes</article-title>. <source>Can J Diabetes</source><year>2005</year>;<volume>29</volume>:<fpage>13</fpage>â<lpage>8</lpage>.</mixed-citation>
              </ref>
              <ref id="R12">
                <label>12</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Frank</surname><given-names>M</given-names></string-name></person-group>. <article-title>Factors associated with non-compliance with a medical follow-up regimen after discharge from a pediatric diabetes clinic</article-title>. <source>Can J Diabetes</source><year>1996</year>;<volume>20</volume>:<fpage>13</fpage>â<lpage>20</lpage>.</mixed-citation>
              </ref>
              <ref id="R13">
                <label>13</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Van Walleghem</surname><given-names>N</given-names></string-name>, <string-name><surname>Macdonald</surname><given-names>CA</given-names></string-name>, <string-name><surname>Dean</surname><given-names>HJ</given-names></string-name></person-group>. <article-title>Evaluation of a systems navigator model for transition from pediatric to adult care for young adults with type 1 diabetes</article-title>. <source>Diabetes Care</source><year>2008</year>;<volume>31</volume>:<fpage>1529</fpage>â<lpage>30</lpage>. <pub-id pub-id-type="doi">10.2337/dc07-2247</pub-id><pub-id pub-id-type="pmid">18458141</pub-id></mixed-citation>
              </ref>
              <ref id="R14">
                <label>14</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Butalia</surname><given-names>S</given-names></string-name>, <string-name><surname>Crawford</surname><given-names>SG</given-names></string-name>, <string-name><surname>McGuire</surname><given-names>KA</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Improved transition to adult care in youth with type 1 diabetes: a pragmatic clinical trial</article-title>. <source>Diabetologia</source><year>2021</year>;<volume>64</volume>:<fpage>758</fpage>â<lpage>66</lpage>. <pub-id pub-id-type="doi">10.1007/s00125-020-05368-1</pub-id><pub-id pub-id-type="pmid">33439284</pub-id></mixed-citation>
              </ref>
              <ref id="R15">
                <label>15</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Spaic</surname><given-names>T</given-names></string-name>, <string-name><surname>Robinson</surname><given-names>T</given-names></string-name>, <string-name><surname>Goldbloom</surname><given-names>E</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Closing the gap: results of the multicenter Canadian randomized controlled trial of structured transition in young adults with type 1 diabetes</article-title>. <source>Diabetes Care</source><year>2019</year>;<volume>42</volume>:<fpage>1018</fpage>â<lpage>26</lpage>. <pub-id pub-id-type="doi">10.2337/dc18-2187</pub-id><pub-id pub-id-type="pmid">31010873</pub-id></mixed-citation>
              </ref>
              <ref id="R16">
                <label>16</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bisno</surname><given-names>DI</given-names></string-name>, <string-name><surname>Reid</surname><given-names>MW</given-names></string-name>, <string-name><surname>Fogel</surname><given-names>JL</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Virtual group appointments reduce distress and improve care management in young adults with type 1 diabetes</article-title>. <source>J Diabetes Sci Technol</source><year>2022</year>;<volume>16</volume>:<fpage>1419</fpage>â<lpage>27</lpage>. <pub-id pub-id-type="doi">10.1177/19322968211035768</pub-id><pub-id pub-id-type="pmid">34328029</pub-id></mixed-citation>
              </ref>
              <ref id="R17">
                <label>17</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Coad</surname><given-names>J</given-names></string-name>, <string-name><surname>Toft</surname><given-names>A</given-names></string-name>, <string-name><surname>Claridge</surname><given-names>L</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Using mobile phone technology to support young liver transplant recipients moving to adult services</article-title>. <source>Prog Transplant</source><year>2017</year>;<volume>27</volume>:<fpage>207</fpage>â<lpage>18</lpage>. <pub-id pub-id-type="doi">10.1177/1526924817699958</pub-id><pub-id pub-id-type="pmid">28617171</pub-id></mixed-citation>
              </ref>
              <ref id="R18">
                <label>18</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Deacon</surname><given-names>AJ</given-names></string-name>, <string-name><surname>Edirippulige</surname><given-names>S</given-names></string-name></person-group>. <article-title>Using mobile technology to motivate adolescents with type 1 diabetes mellitus: a systematic review of recent literature</article-title>. <source>J Telemed Telecare</source><year>2015</year>;<volume>21</volume>:<fpage>431</fpage>â<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1177/1357633X15605223</pub-id><pub-id pub-id-type="pmid">26377124</pub-id></mixed-citation>
              </ref>
              <ref id="R19">
                <label>19</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Los</surname><given-names>E</given-names></string-name>, <string-name><surname>Ulrich</surname><given-names>J</given-names></string-name>, <string-name><surname>Guttmann-Bauman</surname><given-names>I</given-names></string-name></person-group>. <article-title>Technology use in transition-age patients with type 1 diabetes</article-title>. <source>J Diabetes Sci Technol</source><year>2016</year>;<volume>10</volume>:<fpage>662</fpage>â<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1177/1932296816632543</pub-id><pub-id pub-id-type="pmid">26892506</pub-id></mixed-citation>
              </ref>
              <ref id="R20">
                <label>20</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hanauer</surname><given-names>DA</given-names></string-name>, <string-name><surname>Wentzell</surname><given-names>K</given-names></string-name>, <string-name><surname>Laffel</surname><given-names>N</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Computerized automated reminder diabetes system (cards): e-mail and SMS cell phone text messaging reminders to support diabetes management</article-title>. <source>Diabetes Technol Ther</source><year>2009</year>;<volume>11</volume>:<fpage>99</fpage>â<lpage>106</lpage>. <pub-id pub-id-type="doi">10.1089/dia.2008.0022</pub-id><pub-id pub-id-type="pmid">19848576</pub-id></mixed-citation>
              </ref>
              <ref id="R21">
                <label>21</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Huang</surname><given-names>JS</given-names></string-name>, <string-name><surname>Terrones</surname><given-names>L</given-names></string-name>, <string-name><surname>Tompane</surname><given-names>T</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Preparing adolescents with chronic disease for transition to adult care: a technology program</article-title>. <source>Pediatrics</source><year>2014</year>;<volume>133</volume>:<fpage>e1639</fpage>â<lpage>46</lpage>. <pub-id pub-id-type="doi">10.1542/peds.2013-2830</pub-id><pub-id pub-id-type="pmid">24843066</pub-id></mixed-citation>
              </ref>
              <ref id="R22">
                <label>22</label>
                <mixed-citation publication-type="other"><article-title>Guidelines for the economic evaluation of health technologies: Canada. 4th edn</article-title>. <year>2017</year>:<fpage>76</fpage>.</mixed-citation>
              </ref>
              <ref id="R23">
                <label>23</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Husereau</surname><given-names>D</given-names></string-name>, <string-name><surname>Drummond</surname><given-names>M</given-names></string-name>, <string-name><surname>Augustovski</surname><given-names>F</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Consolidated health economic evaluation reporting standards 2022 (cheers 2022) statement: updated reporting guidance for health economic evaluations</article-title>. <source>BMJ</source><year>2022</year>;<volume>376</volume>:<elocation-id>e067975</elocation-id>. <pub-id pub-id-type="doi">10.1136/bmj-2021-067975</pub-id><pub-id pub-id-type="pmid">35017145</pub-id></mixed-citation>
              </ref>
              <ref id="R24">
                <label>24</label>
                <mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Braun</surname><given-names>V</given-names></string-name>, <string-name><surname>Clarke</surname><given-names>V</given-names></string-name>, <string-name><surname>Hayfield</surname><given-names>N</given-names></string-name>, <etal>et al</etal></person-group>. <part-title>Thematic analysis</part-title>. In: <person-group person-group-type="editor"><string-name><surname>Liamputtong</surname><given-names>P</given-names></string-name></person-group>, ed. <source>Handbook of Research Methods in Health Social Sciences</source>. <publisher-loc>Singapore</publisher-loc>: <publisher-name>Springer Singapore</publisher-name>, <year>2019</year>: <fpage>843</fpage>â<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1007/978-981-10-5251-4</pub-id></mixed-citation>
              </ref>
              <ref id="R25">
                <label>25</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>McLeroy</surname><given-names>KR</given-names></string-name>, <string-name><surname>Bibeau</surname><given-names>D</given-names></string-name>, <string-name><surname>Steckler</surname><given-names>A</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>An ecological perspective on health promotion programs</article-title>. <source>Health Educ Q</source><year>1988</year>;<volume>15</volume>:<fpage>351</fpage>â<lpage>77</lpage>. <pub-id pub-id-type="doi">10.1177/109019818801500401</pub-id><pub-id pub-id-type="pmid">3068205</pub-id></mixed-citation>
              </ref>
              <ref id="R26">
                <label>26</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Corathers</surname><given-names>SD</given-names></string-name>, <string-name><surname>Yi-Frazier</surname><given-names>JP</given-names></string-name>, <string-name><surname>Kichler</surname><given-names>JC</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Development and implementation of the readiness assessment of emerging adults with type 1 diabetes diagnosed in youth (READDY) tool</article-title>. <source>Diabetes Spectr</source><year>2020</year>;<volume>33</volume>:<fpage>99</fpage>â<lpage>103</lpage>. <pub-id pub-id-type="doi">10.2337/ds18-0075</pub-id><pub-id pub-id-type="pmid">32116461</pub-id></mixed-citation>
              </ref>
              <ref id="R27">
                <label>27</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cianci</surname><given-names>R</given-names></string-name>, <string-name><surname>Yan</surname><given-names>Z</given-names></string-name>, <string-name><surname>Shulman</surname><given-names>R</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Online educational resources for youth transitioning to adult diabetes care: an environmental scan of Canadian content</article-title>. <source>Canadian Journal of Diabetes</source><year>2021</year>;<volume>45</volume>:<elocation-id>S14</elocation-id>. <pub-id pub-id-type="doi">10.1016/j.jcjd.2021.09.045</pub-id></mixed-citation>
              </ref>
              <ref id="R28">
                <label>28</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pampalon</surname><given-names>R</given-names></string-name>, <string-name><surname>Hamel</surname><given-names>D</given-names></string-name>, <string-name><surname>Gamache</surname><given-names>P</given-names></string-name></person-group>. <article-title>A comparison of individual and area-based socio-economic data for monitoring social inequalities in health</article-title>. <source>Health Rep</source><year>2009</year>;<volume>20</volume>:<fpage>85</fpage>â<lpage>94</lpage>.<pub-id pub-id-type="pmid">20108609</pub-id></mixed-citation>
              </ref>
              <ref id="R29">
                <label>29</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pampalon</surname><given-names>R</given-names></string-name>, <string-name><surname>Hamel</surname><given-names>D</given-names></string-name>, <string-name><surname>Gamache</surname><given-names>P</given-names></string-name></person-group>. <article-title>Health inequalities, deprivation, immigration and Aboriginality in Canada: a geographic perspective</article-title>. <source>Can J Public Health</source><year>2010</year>;<volume>101</volume>:<fpage>470</fpage>â<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1007/BF03403966</pub-id><pub-id pub-id-type="pmid">21370783</pub-id></mixed-citation>
              </ref>
              <ref id="R30">
                <label>30</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hanas</surname><given-names>R</given-names></string-name>, <string-name><surname>John</surname><given-names>G</given-names></string-name>, <collab>International HBA1c Consensus Committee</collab></person-group>. <article-title>2010 consensus statement on the worldwide standardization of the hemoglobin A1c measurement</article-title>. <source>Diabetes Care</source><year>2010</year>;<volume>33</volume>:<fpage>1903</fpage>â<lpage>4</lpage>. <pub-id pub-id-type="doi">10.2337/dc10-0953</pub-id><pub-id pub-id-type="pmid">20519665</pub-id></mixed-citation>
              </ref>
              <ref id="R31">
                <label>31</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Locke</surname><given-names>EA</given-names></string-name></person-group>. <article-title>Self-Efficacy: the exercise of control</article-title>. <source>Pers Psychol</source><year>1997</year>;<volume>50</volume>:<fpage>801</fpage>.</mixed-citation>
              </ref>
              <ref id="R32">
                <label>32</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Holden</surname><given-names>G</given-names></string-name></person-group>. <article-title>The relationship of self-efficacy appraisals to subsequent health related outcomes</article-title>. <source>Social Work in Health Care</source><year>1992</year>;<volume>16</volume>:<fpage>53</fpage>â<lpage>93</lpage>. <pub-id pub-id-type="doi">10.1300/J010v16n01_05</pub-id><pub-id pub-id-type="pmid">1589825</pub-id></mixed-citation>
              </ref>
              <ref id="R33">
                <label>33</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Iannotti</surname><given-names>RJ</given-names></string-name>, <string-name><surname>Schneider</surname><given-names>S</given-names></string-name>, <string-name><surname>Nansel</surname><given-names>TR</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Self-Efficacy, outcome expectations, and diabetes self-management in adolescents with type 1 diabetes</article-title>. <source>J Dev Behav Pediatr</source><year>2006</year>;<volume>27</volume>:<fpage>98</fpage>â<lpage>105</lpage>. <pub-id pub-id-type="doi">10.1097/00004703-200604000-00003</pub-id><pub-id pub-id-type="pmid">16682872</pub-id></mixed-citation>
              </ref>
              <ref id="R34">
                <label>34</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mulvaney</surname><given-names>SA</given-names></string-name>, <string-name><surname>Hood</surname><given-names>KK</given-names></string-name>, <string-name><surname>Schlundt</surname><given-names>DG</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Development and initial validation of the barriers to diabetes adherence measure for adolescents</article-title>. <source>Diabetes Res Clin Pract</source><year>2011</year>;<volume>94</volume>:<fpage>77</fpage>â<lpage>83</lpage>. <pub-id pub-id-type="doi">10.1016/j.diabres.2011.06.010</pub-id><pub-id pub-id-type="pmid">21737172</pub-id></mixed-citation>
              </ref>
              <ref id="R35">
                <label>35</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kosse</surname><given-names>RC</given-names></string-name>, <string-name><surname>Bouvy</surname><given-names>ML</given-names></string-name>, <string-name><surname>Belitser</surname><given-names>SV</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Effective engagement of adolescent asthma patients with mobile health-supporting medication adherence</article-title>. <source>JMIR Mhealth Uhealth</source><year>2019</year>;<volume>7</volume>:<elocation-id>e12411</elocation-id>. <pub-id pub-id-type="doi">10.2196/12411</pub-id><pub-id pub-id-type="pmid">30916664</pub-id></mixed-citation>
              </ref>
              <ref id="R36">
                <label>36</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Addala</surname><given-names>A</given-names></string-name>, <string-name><surname>Auzanneau</surname><given-names>M</given-names></string-name>, <string-name><surname>Miller</surname><given-names>K</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>A decade of disparities in diabetes technology use and HbA1c in pediatric type 1 diabetes: a transatlantic comparison</article-title>. <source>Diabetes Care</source><year>2021</year>;<volume>44</volume>:<fpage>133</fpage>â<lpage>40</lpage>. <pub-id pub-id-type="doi">10.2337/dc20-0257</pub-id><pub-id pub-id-type="pmid">32938745</pub-id></mixed-citation>
              </ref>
              <ref id="R37">
                <label>37</label>
                <mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>Inflation Calculator</collab></person-group>. <article-title>Bank of Canada</article-title>. <year>2021</year>. <comment>Available</comment>: <uri xlink:href="https://www.bankofcanada.ca/rates/related/inflation-calculator">https://www.bankofcanada.ca/rates/related/inflation-calculator</uri> [Accessed <comment>7 Dec 2022</comment>].</mixed-citation>
              </ref>
              <ref id="R38">
                <label>38</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Slattery</surname><given-names>P</given-names></string-name>, <string-name><surname>Saeri</surname><given-names>AK</given-names></string-name>, <string-name><surname>Bragge</surname><given-names>P</given-names></string-name></person-group>. <article-title>Research co-design in health: a rapid overview of reviews</article-title>. <source>Health Res Policy Syst</source><year>2020</year>;<volume>18</volume>:<fpage>17</fpage>. <pub-id pub-id-type="doi">10.1186/s12961-020-0528-9</pub-id><pub-id pub-id-type="pmid">32046728</pub-id></mixed-citation>
              </ref>
              <ref id="R39">
                <label>39</label>
                <mixed-citation publication-type="webpage"><article-title>Table 22-10-0143-01 smartphone personal use and selected smartphone habits by gender and age group: Statistics Canada</article-title>. <year>2021</year>. <comment>Available</comment>: <uri xlink:href="https://www150.statcan.gc.ca/t1/tbl1/en/tv.action?pid=2210014301">https://www150.statcan.gc.ca/t1/tbl1/en/tv.action?pid=2210014301</uri> [Accessed <comment>7 Dec 2022</comment>].</mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
